← All trials
NCT05722691
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 9, 2022
- Primary completion
- Nov 22, 2022
- Completion date
- Jan 17, 2023
- First posted
- Feb 10, 2023
- Last posted
- Feb 16, 2023
- Enrollment
- 800
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Promomed, LLCLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.